0001178913-23-001111.txt : 20230323 0001178913-23-001111.hdr.sgml : 20230323 20230323073531 ACCESSION NUMBER: 0001178913-23-001111 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230316 FILED AS OF DATE: 20230323 DATE AS OF CHANGE: 20230323 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Cohen Neil Harris CENTRAL INDEX KEY: 0001840006 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38807 FILM NUMBER: 23754481 MAIL ADDRESS: STREET 1: C/O ANCHIANO THERAPEUTICS LTD. STREET 2: ONE KENDALL SQ., BLDG 1400E, STE 14-105 CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Chemomab Therapeutics Ltd. CENTRAL INDEX KEY: 0001534248 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 813676773 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: KIRYAT ATIDIM, BUILDING 7 CITY: TEL AVIV STATE: L3 ZIP: 6158002 BUSINESS PHONE: 972-77-331-0156 MAIL ADDRESS: STREET 1: KIRYAT ATIDIM, BUILDING 7 CITY: TEL AVIV STATE: L3 ZIP: 6158002 FORMER COMPANY: FORMER CONFORMED NAME: Anchiano Therapeutics Ltd. DATE OF NAME CHANGE: 20180906 FORMER COMPANY: FORMER CONFORMED NAME: BioCancell Ltd. DATE OF NAME CHANGE: 20111104 4 1 zk2329428.xml X0407 4 2023-03-16 0 0001534248 Chemomab Therapeutics Ltd. CMMB 0001840006 Cohen Neil Harris C/O CHEMOMAB THERAPEUTICS LTD., 1 KENDALL SQ, BLDG 1400E, STE 14-105 CAMBRIDGE MA 02139 1 0 0 0 0 American Depositary Shares 10000 D Option to Purchase American Depositary Shares 1.62 2023-03-16 4 A 0 6875 0 A 2033-03-21 American Depositary Shares 6875 6875 D Option to Purchase American Depositary Shares 3.53 2022-03-07 4 A 0 6820 0 A 2032-03-07 American Depositary Shares 6820 6820 D Option to Purchase American Depositary Shares 27.26 2021-04-19 4 A 0 11884 0 A 2031-04-19 American Depositary Shares 11884 11884 D Option to Purchase American Depositary Shares 13.17 2021-03-16 4 A 0 688 0 A 2030-07-15 American Depositary Shares 688 688 D Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer. No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only. These options were granted as per the annual grant of options to directors. Those options vest and become exercisable in their entirety on March 16, 2024, subject to the Reporting Person's continued service. These options vested and became exercisable in their entirety on March 16, 2023. These options were granted as per the annual grant of options to directors These options vest and become exercisable in equal monthly installments over a 36 month period commencing on March 16, 2021, subject to the Reporting Person's continued service. These options vest and become exercisable as follows: 1/3 vested on July 16, 2021, and the remaining options vest on a quarterly basis for the following eight quarters, subject to the Reporting Person's continued service. /s/ Neil Cohen 2023-03-23